Alectinib induced CNS radiation necrosis in an ALK + NSCLC patient with a remote (7 years) history of brain radiation. (June 2016)

• Record Type: Journal Article
• Authors: Ou, Sai-Hong Ignatius; Weitz, Michael; Jalas, John R.; Kelly, Daniel F.; Wong, Vanessa; Azada, Michele C.; Quines, Oliver; Klempner, Samuel J.
• Is Part Of: Lung cancer. Volume 96(2016)
• Page Start: 15
• Page End: 18
• Publication Date: 2016-06
• Subjects: Pseudo-progression -- Radiation necrosis -- Alectinib -- ALK-positive non-small cell lung cancer; Lungs -- Cancer -- Periodicals; Lung Neoplasms -- Abstracts; Lung Neoplasms -- Periodicals; Poumons -- Cancer -- Périodiques; Lungs -- Cancer; Periodicals; Electronic journals; Electronic journals; 616.99424
• DOI: 10.1016/j.lungcan.2016.03.008
• Languages: English
• ISSNs: 0169-5002

Abstract

Highlights: Alectinib can induce CNS necrosis after long treatment. Alectinib can induce CNS necrosis in the setting of remote brain radiation. Important to have clinical awareness to identify treatment-related necrosis. Abstract: Alectinib is a second generation ALK inhibitor that has significant clinical activity in central nervous system (CNS) metastases in anaplastic lymphoma kinase ( ALK )-rearranged non-small cell lung cancer (NSCLC). Pseudoprogression (PsP) due to radiation necrosis during alecitnib treatment of central nervous system (CNS) metastases from ALK -rearranged NSCLC as been reported. Hence, distinguishing radiation-related PsP from alectinib-induced radiographic changes is important to avoid erroneous early trial discontinuation and abandonment of an effective treatment. However, it remains difficult to assess casuality of radiation necrosis is related to recent direct radiation or induced by alectinib treatment or both. It is also unknown how long from previous radiation can alectinib still induce radiation necrosis. Here we reported a crizotinib-refractory ALK -positive NSCLC patient who develop radiation necrosis in one of his metastatic CNS lesions after approximately 12 months of alectinib treatment who otherwise had on-going CNS response on alectinib. His most recent radiation to his CNS metastases was 7 years prior to the start of alectinib. This case illustrates that in the setting of pror CNS radiation, given the significant clinical activity of alectinib in CNS metastases in ALK -positive NSCLC patients the risk of CNS radiation necrosis remains long after previous radiation to the CNS metastases has been completed and can occur after durable response of treatment.